OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Organization: Case Western Reserve University

7 Projects | 4 Researchers | $1,826,855 Invested

2016

Case Western Reserve University

Xinglong Wang, PhD

Mitochondrial TDP-43 as a Novel Therapeutic Target for FTD

  • Funding Amount: $150,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: TDP-43
  • Status: Closed

2016

Case Western Reserve University

Irina Pikuleva, PhD

Cholesterol-metabolizing enzyme CYP46A1 as a new therapeutic target for Alzheimer's disease

  • Funding Amount: $794,596
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Target: Other
  • Status: Closed

2005

Case Western Reserve University

Robert Friedland, MD

Regional Symposium on Alzheimer's Disease and Related Disorders in the Middle East

  • Funding Amount: $3,000
  • Organization Type: Academic/Nonprofit
  • Program: Conferences/Other
  • Status: Closed

2001

Case Western Reserve University

Robert Friedland, MD

International Symposium on Alzheimer's Disease in Middle East

  • Funding Amount: $20,000
  • Organization Type: Academic/Nonprofit
  • Program: Conferences/Other
  • Status: Closed

2000

Case Western Reserve University

Robert Friedland, MD

Genetic and Environmental Risk Factors for Alzheimer's Disease in Israeli Arabs (Part 2)

  • Funding Amount: $210,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

1999

Case Western Reserve University

Robert Friedland, MD

Genetic and Environmental Risk Factors for Alzheimer's Disease in Israeli Arabs

  • Funding Amount: $50,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

Case Western Reserve University

Paul Tesar, PhD

Therapeutic neuroprotection in Alzheimer’s disease through controlling toxic astrocytes

  • Funding Amount: $599,259
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Neuronal Degeneration
  • Status: Active